Inactief instrument

Andere talen Reshape Lifesciences Inc Nasdaq

Aandelen

US7611231082

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q1 Revenue $1.9M, vs. Street Est of $2.1M	15/05
ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update	15/05
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update	14/05
North American Morning Briefing : Big Banks Kick -2-	12/04
ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update	01/04
ReShape Lifesciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Certain Restricted Stock Units of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	30/03
Certain Warrants of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	30/03
Certain Options of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	30/03
Certain Common Stock of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	30/03
ReShape Lifesciences Gets US Patent for Intragastric Balloon Weight-Loss System	28/03
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System	28/03
ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System	28/03
ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX	04/03
ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX	22/02
Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex	22/02
ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX	24/01
ReShape Lifesciences announces FDA PMA supplement approval for next-gen Lap-Band 2.0 Flex	21/12
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives	20/12
Top Midday Gainers	13/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Reshape Lifesciences Inc Nasdaq

Aandelen

US7611231082

Andere talen

Filters